» Articles » PMID: 33106977

Pentoxifylline, Tocopherol, and Sequestrectomy Are Effective for the Management of Advanced Osteoradionecrosis of the Jaws-a Case Series

Abstract

Background: The aim of the present study was to evaluate the efficacy of pentoxifylline and tocopherol for the management of osteoradionecrosis of the jaws.

Methods: Twenty-five patients diagnosed with osteoradionecrosis of the jaws treated with pentoxifylline 400 mg + tocopherol 400 mg three times daily (tid) were evaluated. Clinical records and image tests were reviewed. All patients were previously submitted to head and neck radiation therapy and presented with a clinical and radiographic diagnosis of osteoradionecrosis of the jaws.

Results: Following therapy with pentoxifylline and tocopherol, 76% (19/25) of the patients showed complete mucosal healing, in which 47.3% (9/19) did not undergo sequestrectomy. From this particular group, 77.7% (7/9) were in stage I and 33.3% (3/9) used the protocol for up to 3 months. Among those who underwent to sequestrectomy, complete mucosal healing was observed in 52.7% (10/19). Among these, 60% (6/10) were in stage I and 100% of the patients were using the protocol for more than 3 months. In all other patients, partial healing of the mucosa was observed since they presented advanced disease. These represented 24% of the sample (6/25), 66.6% (4/6) were in stage III, and 60% (4/6) used the protocol for over 6 months.

Conclusion: Pentoxifylline and tocopherol may provide effective management of osteoradionecrosis of the jaws, and the association with sequestrectomy may avoid major surgical procedures.

Citing Articles

Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol.

Slowik L, Toton E, Nowak A, Wysocka-Slowik A, Okla M, Slebioda Z J Clin Med. 2025; 14(3).

PMID: 39941644 PMC: 11818125. DOI: 10.3390/jcm14030974.


Oral health related-quality of life before and during the COVID-19 pandemic in patients with non-alcoholic fatty liver disease.

Aguiar I, Carvalho F, Santos-Lins L, Brasil-Oliveira R, Brites C, Cotrim H Med Oral Patol Oral Cir Bucal. 2023; 28(4):e310-e316.

PMID: 36641744 PMC: 10314354. DOI: 10.4317/medoral.25731.


Pentoxifylline and tocopherol for the treatment of osteoradionecrosis of the jaws. A systematic review.

Arqueros-Lemus M, Marino-Recabarren D, Niklander S, Martinez-Flores R, Moraga V Med Oral Patol Oral Cir Bucal. 2023; 28(3):e293-e300.

PMID: 36641743 PMC: 10181025. DOI: 10.4317/medoral.25729.


Advances and Controversies in the Management of Osteoradionecrosis After Head and Neck Cancer Treatment: A Narrative Review.

Raj R, Nair A, Krishnan N, Balasubramanian D, Iyer S, Thankappan K J Maxillofac Oral Surg. 2022; 21(3):836-844.

PMID: 36274865 PMC: 9475005. DOI: 10.1007/s12663-021-01680-4.